Tisagenlecleucel - Novartis/University of Pennsylvania
Alternative Names: Anti-CD19-CAR transduced T cells - Novartis/University of Pennsylvania; Anti-CD19-chimeric-antigen-receptor-peripheral-blood-lymphocytes-Novartis; Anti-CD19-chimeric-antigen-receptor-retroviral-vector-transduced-autologous-T-cells-Novartis; Anti-CD19-chimeric-immune-receptor-retroviral-vector-transduced-autologous-T-cells-Novartis; Anti-CD19-CIR-retroviral-vector-transduced-autologous-T-cell-therapy-Novartis; CART-019; CART-19; CART-19 cells; CART-19-cells-Novartis; CART19-Novartis; CD19-targeted-chimeric-antigen-receptor-immunotherapy-Novartis; Chimeric antigen receptor-modified T cells against CD19 - University of Pennsylvania/Novartis; CTL-019; Kimria; Kymriah; LG-740; tisagenlecleucel; tisagenlecleucel-TLatest Information Update: 02 Jan 2025
At a glance
- Originator Lentigen Corporation; University of Pennsylvania
- Developer Beijing Sanwater Biological Technology; Novartis; University of Pennsylvania
- Class Antineoplastics; CAR-T cell therapies; Cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Diffuse large B cell lymphoma; Follicular lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
- Phase III Non-Hodgkin's lymphoma
- Phase II Multiple myeloma
- No development reported B-cell lymphoma; B-cell prolymphocytic leukaemia; Breast cancer; Lymphoma; Mantle-cell lymphoma; Mesothelioma; Ovarian cancer; Pancreatic cancer
- Discontinued Chronic lymphocytic leukaemia
Most Recent Events
- 02 Jan 2025 3882226- Real world data hence not covered
- 07 Dec 2024 Clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (In adolescents, In children, In neonates) (Parenteral) prior to December 2024
- 07 Dec 2024 Interim efficacy data from a clinical trial in Precursor B-cell lymphoblastic leukaemia-lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-2024)